Agilent raises outlook after Q2 earnings beat by 6%

Agilent Technologies raised its full-year outlook after Q2 revenue of $1.83 billion beat consensus by 2.1%, driven by instrument replacement cycles and pricing gains.

"Our strong Q2 results reflect the success of our strategic initiatives and our commitment to innovation," Chief Executive Officer Padraig McDonnell said. "We are confident in our ability to deliver sustained growth and value to our shareholders."

Non-GAAP earnings per share rose 14% to $1.49, topping the $1.41 analyst estimate by $0.08. Operating margin expanded 130 basis points to 26.4%, while gross margin improved 90 basis points to 55%. Revenue grew 10% from $1.67 billion a year earlier, or 6.3% on a core constant-currency basis.

Metric	Actual	Consensus	Beat/Miss
Revenue	$1.83B	$1.80B	+1.7%
EPS (non-GAAP)	$1.49	$1.41	+5.7%
Operating Margin	26.4%	—	+130 bps YoY

The laboratory supplies and services company now expects full-year adjusted earnings of $6.00 to $6.10 a share on revenue of $7.39 billion to $7.49 billion, up from its prior forecast of $5.90 to $6.04 and $7.3 billion to $7.5 billion, respectively. For the third quarter, Agilent forecast adjusted EPS of $1.48 to $1.50 on revenue of $1.83 billion to $1.85 billion, largely in line with analyst estimates.

Strength was broad across end markets. Pharma revenue grew 6%, with biotech posting low-double-digit growth for a third straight quarter. Chemicals and advanced materials rose 8%, fueled by semiconductor demand and capital spending in the Americas. Diagnostics and clinical climbed 11%, driven by cancer diagnostics and the Omnis product family. Environmental and forensics grew 13%, including more than 50% growth in forensics from a Transportation Security Administration airport security contract and competitive tender wins in Asia and Europe.

McDonnell said the company's Ignite operating system delivered about 200 basis points of pricing in the quarter, putting Agilent on track to exceed its full-year goal of 100 basis points. The company also fully offset the operating profit impact of incremental tariffs through manufacturing moves and price adjustments.

Shares rose 5.3% to $122.00 in after-hours trading, reflecting investor confidence in the raised guidance and margin trajectory. The guidance raise signals management expects demand momentum to continue through the second half. Investors will watch the Q3 earnings call for updates on the planned Biocare acquisition and further margin expansion from the Ignite program.

This article is for informational purposes only and does not constitute investment advice.